<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03686150</url>
  </required_header>
  <id_info>
    <org_study_id>101</org_study_id>
    <nct_id>NCT03686150</nct_id>
  </id_info>
  <brief_title>Vitamin D Oral Replacement in Asthma</brief_title>
  <acronym>VDORA1</acronym>
  <official_title>Vitamin D Oral Replacement in Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IDeA States Pediatric Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IDeA States Pediatric Clinical Trials Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of the study is to determine the pharmacokinetics of Vitamin D
      supplementation in children who have asthma and are overweight or obese.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has two parts. In part 1, study participants will be randomized to receive one of
      four doses of vitamin D supplementation in international units (IU) over at 16-week period:
      1) Single 50,000 IU loading dose + 6000 IU daily dose; 2) Single 50,000 IU loading dose +
      10,000 IU daily dose: 3) 6000 IU daily dose; or 4) 600 IU daily dose. Based on
      pharmacokinetic analysis, one of the doses (1-3) will be selected to use in part 2.

      In part 2, study participants will be randomized to the dose selected in part 1 or the 600 IU
      daily dose of vitamin D supplementation to be administered over a 16-week dosing period.

      Across both parts, safety of each dose regimen of vitamin D supplementation will be
      evaluated, and the effectiveness of each dose to achieve a serum level of 25(OH)D greater
      than or equal to 40 ng/ml will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 30, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, parallel arm clinical trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best dosing level of vitamin D supplementation</measure>
    <time_frame>20 weeks</time_frame>
    <description>Determine the best vitamin D supplementation level based on PK analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: optimal dosing level to use in part 2</measure>
    <time_frame>20 weeks</time_frame>
    <description>Based on part 1 data, determine the best vitamin D supplementation level based on PK analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Proportion of participants with vitamin D levels &gt;= 40 ng/ml</measure>
    <time_frame>16 weeks</time_frame>
    <description>Proportion of participants in part 2 who achieve vitamin levels &gt;= 40 ng/ml</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">89</enrollment>
  <condition>Asthma</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Pediatric Obesity</condition>
  <arm_group>
    <arm_group_label>Part 1, Cohort 1 Vitamin D3 oral regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Vitamin D: Single 50,000 IU loading dose + 6000 IU daily dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 2 Vitamin D3 oral regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D: Single 50,000 IU loading dose + 10,000 IU daily dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 3 Vitamin D3 oral regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D: 6000 IU daily dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 4 Vitamin D3 oral regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D: 600 IU daily dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 oral regimen</intervention_name>
    <description>Vitamin D3 oral regimens supplementation</description>
    <arm_group_label>Part 1, Cohort 1 Vitamin D3 oral regimen</arm_group_label>
    <arm_group_label>Part 1, Cohort 2 Vitamin D3 oral regimen</arm_group_label>
    <arm_group_label>Part 1, Cohort 3 Vitamin D3 oral regimen</arm_group_label>
    <arm_group_label>Part 1, Cohort 4 Vitamin D3 oral regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index greater than or equal to 85% for age and sex

          -  Physician-diagnosed asthma

          -  Ongoing relationship with asthma provider responsible for asthma care

          -  Serum 25(OH) D level 10 ng/ml to less than 30 ng/ml at screening visit based on local
             laboratory test

          -  Ability to swallow pills similar in size to the vitamin D preparation to be used

          -  Signed consent form from parent, legal guardian or caregiver and signed assent from
             participant (as appropriate)

          -  Females of childbearing years must not be pregnant, must not be lactating and must
             agree to practice adequate birth control method

          -  Child and parent, legal guardian, or caregiver must speak English or Spanish

        Exclusion Criteria:

          -  Known diseases of calcium metabolism or the parathyroid

          -  History of renal insufficiency or kidney stones

          -  Known liver failure or history of abnormal liver function tests

          -  History of Williams syndrome, sarcoidosis, or granulomatous disease

          -  Active tuberculosis

          -  Spot urine calcium/creatinine ration greater than 0.37 (calcium and creatinine
             measured in mg/ml). This can be repeated following adequate hydration

          -  Clinical evidence of rickets

          -  Taking supplemental vitamin D greater than equal to 1000 IU per day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours/Alfred I duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Medical Center</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center/Children's Hospital and Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hospital - Manchester</name>
      <address>
        <city>Manchester</city>
        <state>New Hampshire</state>
        <zip>03104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Health Sciences Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital OU Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Carolina</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

